Products for Research Use Only
RegisterLogin

Obatoclax

CAT: 0804-HY-10969ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10969ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Obatoclax (GX15-070), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2[1][2]. Obatoclax induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax has anti-cancer and broad-spectrum antiparasitic activity[3][4].
CAS Number
803712-67-6
Product Name Alternative
GX15-070
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Bcl-2 Family; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/obatoclax-1.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
COC1=CC(C(N2)=CC3=C2C=CC=C3)=N/C1=C\C4=C(C)C=C(C)N4
Molecular Formula
C20H19N3O
Molecular Weight
317.38
Precautions
H302, H315, H319, H335
References & Citations
[1]Or CR, et al. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells. Int J Mol Sci. 2016 Dec 27;18 (1) .|[2]Sulkshane P, et al. BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget. 2016 Aug 5;8 (36) :60060-60079.|[3]Ehrenkaufer G, et al. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. PLoS Negl Trop Dis. 2020 Mar 20;14 (3) :e0008150.|[4]Nguyen M, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007 Dec 4;104 (49) :19512-7. Epub 2007 Nov 26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Bcl-2; Bcl-B; Bcl-W; Bcl-xL; Mcl-1
Citation 01
ACS Infect Dis. 2023 Nov 10;9 (11) :2105-2118.|Acta Pharmacol Sin. 2021 Aug;42 (8) :1298-1310.|Departamento de Biotecnología - Departament de Biotecnologia. 2020 Sep 7. |Am J Cancer Res. 2019 Mar 1;9 (3) :546-561.|Biomed Pharmacother. 2020 Sep;129:110371.|bioRxiv. 2024 Jul 25.|Cancer Lett. 2023 Feb 1:554:216028.|Drug Deliv Transl Res. 2025 Oct 29.|iScience. 2022 Sep 16;25 (9) :104925.|Norwegian University of Science and Technology. Department of Clinical and Molecular Medicine. 2021 Oct.|Sci Rep. 2019 Sep 24;9 (1) :13786.|Viruses. 2020 Oct 18;12 (10) :1178.

Alternative Products

CatalogName
DHB71267-01Obatoclax
461427-01Obatoclax Mesylate
GTR19243982-01Obatoclax B

Popular Products